Segall Bryant & Hamill LLC Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Segall Bryant & Hamill LLC acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 32,061 shares of the company’s stock, valued at approximately $483,000. Segall Bryant & Hamill LLC owned 0.07% of Pacira BioSciences at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Jane Street Group LLC boosted its holdings in shares of Pacira BioSciences by 1,780.2% in the first quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock valued at $5,480,000 after acquiring an additional 177,557 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Pacira BioSciences by 12.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after purchasing an additional 198,936 shares during the period. Legato Capital Management LLC lifted its holdings in shares of Pacira BioSciences by 74.0% during the second quarter. Legato Capital Management LLC now owns 52,913 shares of the company’s stock worth $1,514,000 after purchasing an additional 22,497 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of Pacira BioSciences during the second quarter worth $2,726,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after purchasing an additional 932 shares during the period. 99.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on PCRX. Royal Bank of Canada increased their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Jefferies Financial Group increased their price target on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Raymond James cut Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. reiterated an “underweight” rating and issued a $10.00 price objective (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Finally, HC Wainwright cut their price objective on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Trading Up 1.0 %

Shares of PCRX stock opened at $17.55 on Monday. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The stock has a market cap of $810.28 million, a P/E ratio of -8.65 and a beta of 0.82. The business has a fifty day simple moving average of $16.21 and a 200-day simple moving average of $20.30. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.